Literature DB >> 29067768

Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis.

Zimeng Li1, Yi Li2, Yulong Liu3, Wenbo Xu4, Qing Wang1.   

Abstract

New-onset diabetes mellitus (NOD) refers to forms of diabetes mellitus that develop during the therapeutic processes of other diseases such as hypertension. This study has been conducted in a network meta-analysis to compare antihypertensive drugs by identifying both the advantages and disadvantages on NOD by focusing on their respective effect rates. Odd ratios and corresponding 95% confidence intervals or credible intervals were calculated within pairwise and network meta-analysis. A total of 38 articles with 224 140 patients were included to evaluate the preventive effect of hypertension drugs on NOD. From the network meta-analysis it was evident that both angiotensin-converting enzyme inhibitor as well as angiotensin receptor blocker treatments are associated with a lower risk of developing NOD compared with placebo, with ranking probabilities of 79.81% and 72.77%, respectively, while β-blockers and calcium channel blockers may significantly increase the probability of developing NOD (β-blockers: odds ratio, 2.18 [95% credible intervals: 1.36-3.50]; calcium channel blockers: odds ratio, 1.16 [95% credible intervals, 1.05-1.29]). In conclusion, angiotensin receptor blockers have an advantage over the other treatments regarding the NOD. ©2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  hypertension; network meta-analysis; new-onset diabetes mellitus

Mesh:

Substances:

Year:  2017        PMID: 29067768      PMCID: PMC8030754          DOI: 10.1111/jch.13108

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

Review 1.  Antihypertensive therapy and new onset diabetes.

Authors:  Franz H Messerli; Ehud Grossman; Gastone Leonetti
Journal:  J Hypertens       Date:  2004-10       Impact factor: 4.844

2.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.

Authors:  Georgia Salanti; A E Ades; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2010-08-05       Impact factor: 6.437

3.  Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study.

Authors:  Joshua I Barzilay; Barry R Davis; Sara L Pressel; Jeffrey A Cutler; Paula T Einhorn; Henry R Black; William C Cushman; Charles E Ford; Karen L Margolis; Jamaluddin Moloo; Suzanne Oparil; Linda B Piller; Debra L Simmons; Mary Ellen Sweeney; Paul K Whelton; Nathan D Wong; Jackson T Wright
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-03-06

Review 4.  Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2004-12       Impact factor: 6.041

Review 5.  Mechanisms linking obesity to insulin resistance and type 2 diabetes.

Authors:  Steven E Kahn; Rebecca L Hull; Kristina M Utzschneider
Journal:  Nature       Date:  2006-12-14       Impact factor: 49.962

6.  Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.

Authors:  Pierluigi Costanzo; Pasquale Perrone-Filardi; Mario Petretta; Caterina Marciano; Enrico Vassallo; Paola Gargiulo; Stefania Paolillo; Andrea Petretta; Massimo Chiariello
Journal:  J Hypertens       Date:  2009-06       Impact factor: 4.844

7.  Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.

Authors:  W B Kannel; D L McGee
Journal:  Diabetes Care       Date:  1979 Mar-Apr       Impact factor: 19.112

8.  Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study.

Authors:  Joshua I Barzilay; Peggy Gao; Lars Rydén; Helmut Schumacher; Jeffrey Probstfield; Patrick Commerford; Antonio Dans; Rafael Ferreira; Mátyás Keltai; Ernesto Paolasso; Salim Yusuf; Koon Teo
Journal:  Diabetes Care       Date:  2011-07-25       Impact factor: 19.112

9.  Cost-utility of angiotensin-converting enzyme inhibitor-based treatment compared with thiazide diuretic-based treatment for hypertension in elderly Australians considering diabetes as comorbidity.

Authors:  Enayet K Chowdhury; Zanfina Ademi; John R Moss; Lindon M H Wing; Christopher M Reid
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

10.  Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.

Authors:  L P Hasvold; J Bodegård; M Thuresson; J Stålhammar; N Hammar; J Sundström; D Russell; S E Kjeldsen
Journal:  J Hum Hypertens       Date:  2014-06-26       Impact factor: 3.012

View more
  8 in total

Review 1.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  Diabetol Int       Date:  2020-07-24

2.  Japanese Clinical Practice Guideline for Diabetes 2019.

Authors:  Eiichi Araki; Atsushi Goto; Tatsuya Kondo; Mitsuhiko Noda; Hiroshi Noto; Hideki Origasa; Haruhiko Osawa; Akihiko Taguchi; Yukio Tanizawa; Kazuyuki Tobe; Narihito Yoshioka
Journal:  J Diabetes Investig       Date:  2020-07       Impact factor: 4.232

3.  Comparative risk of new-onset diabetes mellitus for antihypertensive drugs in elderly: A Bayesian network meta-analysis.

Authors:  Jinhua Zhang; Aihua Tong; Yan Dai; Jie Niu; Fengquan Yu; Fangjiang Xu
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-26       Impact factor: 3.738

4.  Comparative risk of new-onset diabetes mellitus for antihypertensive drugs: A network meta-analysis.

Authors:  Zimeng Li; Yi Li; Yulong Liu; Wenbo Xu; Qing Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-10-25       Impact factor: 3.738

5.  Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients.

Authors:  Xian-Tao Zeng; Hong Weng; Jing Xiong; Qiao Huang; Lin-Lu Ma; Ying-Hui Jin; Xing-Huan Wang
Journal:  Front Physiol       Date:  2018-09-24       Impact factor: 4.566

6.  Four-year changes in central fatness, risk of diabetes, and metabolic control in older adults: a cohort study with mediation analysis.

Authors:  Xue Cai; Dan Luo; Shuling Liu; Ruxue Li; Yanhui Lu; Mingzi Li; Shanhu Qiu
Journal:  Korean J Intern Med       Date:  2021-12-16       Impact factor: 2.884

7.  Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.

Authors:  Chia-Pin Lin; Ying-Chang Tung; Fu-Chih Hsiao; Chia-Hung Yang; Yi-Wei Kao; Yu-Sheng Lin; You-Chia Chu; Pao-Hsien Chu
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-29       Impact factor: 3.738

Review 8.  Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.

Authors:  Stefano Omboni; Massimo Volpe
Journal:  Adv Ther       Date:  2018-12-27       Impact factor: 3.845

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.